|
US7014998B2
(en)
|
2000-09-30 |
2006-03-21 |
Yale University |
Screening immunomodulatory agents by CTLA-4 upregulation
|
|
GB0103389D0
(en)
*
|
2001-02-12 |
2001-03-28 |
Novartis Ag |
Organic compounds
|
|
US20050069538A1
(en)
|
2003-09-18 |
2005-03-31 |
Gregorio Aversa |
Therapeutic binding molecules
|
|
WO2003048327A2
(en)
*
|
2001-12-03 |
2003-06-12 |
Abgenix, Inc. |
Anti-cd45rb antibodies for use in treating autoimmune disease and transplant rejection
|
|
US20050069549A1
(en)
|
2002-01-14 |
2005-03-31 |
William Herman |
Targeted ligands
|
|
WO2003061695A1
(en)
*
|
2002-01-17 |
2003-07-31 |
Amgen Inc. |
Methods of regulating cytokine receptor signaling
|
|
RU2005101622A
(ru)
*
|
2002-07-01 |
2006-01-27 |
Савиент Фармасьютикалс, Инк (Us) |
Композиции и способы терапевтического лечения
|
|
WO2004019891A2
(en)
*
|
2002-08-28 |
2004-03-11 |
Sangstat Medical Corporation |
Methods and compostions for immune tolerance
|
|
US20040047858A1
(en)
*
|
2002-09-11 |
2004-03-11 |
Blumberg Richard S. |
Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof
|
|
EP1658096A1
(en)
*
|
2003-08-25 |
2006-05-24 |
PanGenetics B.V. |
Method of inducing immune tolerance
|
|
TW200521231A
(en)
*
|
2003-09-18 |
2005-07-01 |
Novartis Ag |
Therapeutic binding molecules
|
|
WO2007087453A2
(en)
*
|
2006-01-27 |
2007-08-02 |
Cellerant Therapeutics, Inc. |
Compositions and methods for treating haematological proliferative disorders
|
|
EP2029729A2
(en)
*
|
2006-05-31 |
2009-03-04 |
Genzyme Corporation |
Methods of using anti-thymocyte globulin and related agents
|
|
JP5570808B2
(ja)
|
2006-08-18 |
2014-08-13 |
アルゴス・セラピューティクス・インコーポレーテッド |
併用療法におけるｃｄ８３の使用
|
|
EP2063905B1
(en)
|
2006-09-18 |
2014-07-30 |
Raptor Pharmaceutical Inc |
Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
|
|
KR101323540B1
(ko)
|
2007-02-07 |
2013-10-29 |
사이단호진한다이비세이부쯔뵤우겐큐우카이 |
암의 치료제
|
|
WO2013021784A1
(ja)
*
|
2011-08-10 |
2013-02-14 |
ナパジェン ファーマ，インコーポレテッド |
免疫寛容誘導剤
|
|
US20120077778A1
(en)
|
2010-09-29 |
2012-03-29 |
Andrea Bourdelais |
Ladder-Frame Polyether Conjugates
|
|
US9713636B2
(en)
|
2011-02-28 |
2017-07-25 |
Napajen Pharma, Inc. |
Nucleic acid/polysaccharide complex
|
|
EP2742944B1
(en)
*
|
2011-08-10 |
2018-06-27 |
Napajen Pharma, Inc. |
Immune tolerance inducer
|
|
GB201409558D0
(en)
|
2014-05-29 |
2014-07-16 |
Ucb Biopharma Sprl |
Method
|
|
GB201412659D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
|
GB201412658D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
|
US20170226209A1
(en)
*
|
2014-08-01 |
2017-08-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
An anti-cd45rc antibody for use as drug
|
|
GB201601073D0
(en)
*
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201601077D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibody molecule
|
|
GB201601075D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies molecules
|
|
JP2018534264A
(ja)
|
2015-09-28 |
2018-11-22 |
リージェンツ オブ ザ ユニバーシティ オブ ミネソタ |
自己免疫および同種免疫への治療的介入としてのキメラ抗原受容体（ｃａｒ）ｔ細胞
|
|
GB201521382D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201521391D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201521393D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201521383D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl And Ucb Celltech |
Method
|
|
GB201521389D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Method
|
|
IL263744B2
(en)
|
2016-06-17 |
2023-11-01 |
Magenta Therapeutics Inc |
Compositions and methods for the depletion of cd117 plus cells
|
|
CN109641051A
(zh)
|
2016-06-17 |
2019-04-16 |
美真达治疗公司 |
用于耗尽细胞的组合物和方法
|
|
EP3534960A4
(en)
|
2016-11-07 |
2020-05-13 |
Coimmune, Inc. |
SPECIFIC ANTIBODIES MODULATING AND USING THE TLR-4 SIGNALING
|
|
EP3571230A4
(en)
|
2017-01-20 |
2020-12-16 |
Magenta Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR DELETION OF CD137 + CELLS
|
|
EP3514541A1
(de)
*
|
2018-01-17 |
2019-07-24 |
Siemens Healthcare Diagnostics Products GmbH |
Verfahren zur quantitativen bestimmung eines therapeutischen tnf-alpha inhibitors
|
|
WO2020159656A1
(en)
*
|
2019-02-01 |
2020-08-06 |
Actinium Pharmaceuticals, Inc. |
Molecules and their derivatives directed against cd45
|
|
CN111707833A
(zh)
*
|
2020-06-19 |
2020-09-25 |
徐州医科大学 |
小鼠血管内外淋巴细胞识别的方法及其应用
|
|
KR20230122618A
(ko)
|
2020-12-21 |
2023-08-22 |
알로젠 테라퓨틱스 인코포레이티드 |
프로테아제 활성화 cd45-게이트 car
|
|
EP4288455A1
(en)
|
2021-02-03 |
2023-12-13 |
Mozart Therapeutics, Inc. |
Binding agents and methods of using the same
|
|
CN116997654A
(zh)
|
2021-03-17 |
2023-11-03 |
第一三共株式会社 |
编码抗乙酰胆碱受体自身抗体的嵌合受体的基因
|
|
WO2023076876A1
(en)
|
2021-10-26 |
2023-05-04 |
Mozart Therapeutics, Inc. |
Modulation of immune responses to viral vectors
|
|
US20230399375A1
(en)
|
2022-04-15 |
2023-12-14 |
Kyverna Therapeutics, Inc. |
Methods and compositions for treating autoimmune disease
|
|
WO2023240064A1
(en)
|
2022-06-08 |
2023-12-14 |
Kyverna Therapeutics, Inc. |
Methods and compositions for treating autoimmune disease
|
|
CN120554513B
(zh)
*
|
2025-07-28 |
2025-11-21 |
杭州华大生命科学研究院 |
一种抗cd45抗体及其应用
|